This demands the close examining of patients with no evidence of single-organ IgG4-related disease for IMT, and the diagnostic algorithm should contain ALK and ROS1 immunohistochemical finding and, in chosen subjects, an NGS-based fusion examination that includes known IMT- related gene fusions [54]. The gene discussed is ROS1; the disease is inflammatory myofibroblastic tumor.